questionsmedicales.fr
Facteurs biologiques
Pigments biologiques
Pigments biliaires
Bilirubine
Bilirubine : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Bilirubine
Analyse sanguine
Tests de laboratoire
Fonction hépatique
Maladies hépatiques
Obstruction biliaire
Symptômes
5
Hyperbilirubinémie
Jaunisse
Maladies hépatiques
Symptômes
Prévention
5
Ictère néonatal
Prévention
Examens médicaux
Fonction hépatique
Maladies hépatiques
Prévention
Alimentation
Santé du foie
Traitements
5
Hyperbilirubinémie
Traitement
Transfusions sanguines
Anémie hémolytique
Corticostéroïdes
Bilirubine
Photothérapie
Ictère néonatal
Chirurgie
Obstruction biliaire
Complications
5
Complications
Lésions hépatiques
Hyperbilirubinémie
Dommages cérébraux
Obstruction biliaire
Infections
Grossesse
Hyperbilirubinémie
Cirrhose
Insuffisance hépatique
Facteurs de risque
5
Facteurs de risque
Maladies hépatiques
Alcoolisme
Hyperbilirubinémie
Infections virales
Hépatite
Surpoids
Maladies hépatiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Bilirubine : Questions médicales les plus fréquentes",
"headline": "Bilirubine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Bilirubine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-22",
"dateModified": "2026-04-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Bilirubine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pigments biliaires",
"url": "https://questionsmedicales.fr/mesh/D001654",
"about": {
"@type": "MedicalCondition",
"name": "Pigments biliaires",
"code": {
"@type": "MedicalCode",
"code": "D001654",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.193"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Biliverdine",
"alternateName": "Biliverdine",
"url": "https://questionsmedicales.fr/mesh/D001664",
"about": {
"@type": "MedicalCondition",
"name": "Biliverdine",
"code": {
"@type": "MedicalCode",
"code": "D001664",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.193.184.200"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Bilirubine",
"alternateName": "Bilirubin",
"code": {
"@type": "MedicalCode",
"code": "D001663",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Claudio Tiribelli",
"url": "https://questionsmedicales.fr/author/Claudio%20Tiribelli",
"affiliation": {
"@type": "Organization",
"name": "The Liver-Brain Unit \"Rita-Moretti\", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy."
}
},
{
"@type": "Person",
"name": "Libor Vítek",
"url": "https://questionsmedicales.fr/author/Libor%20V%C3%ADtek",
"affiliation": {
"@type": "Organization",
"name": "4th Department of Internal Medicine and Institute of Medical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic."
}
},
{
"@type": "Person",
"name": "Silvia Gazzin",
"url": "https://questionsmedicales.fr/author/Silvia%20Gazzin",
"affiliation": {
"@type": "Organization",
"name": "The Liver-Brain Unit \"Rita-Moretti\", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy."
}
},
{
"@type": "Person",
"name": "Sri Jayanti",
"url": "https://questionsmedicales.fr/author/Sri%20Jayanti",
"affiliation": {
"@type": "Organization",
"name": "The Liver-Brain Unit \"Rita-Moretti\", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy."
}
},
{
"@type": "Person",
"name": "Kosuke Koyano",
"url": "https://questionsmedicales.fr/author/Kosuke%20Koyano",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "No Association of Multiple Sclerosis with",
"datePublished": "2023-07-09",
"url": "https://questionsmedicales.fr/article/37511014",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms241411254"
}
},
{
"@type": "ScholarlyArticle",
"name": "Alemtuzumab for multiple sclerosis.",
"datePublished": "2023-06-05",
"url": "https://questionsmedicales.fr/article/37272540",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD011203.pub3"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Treatment of multiple sclerosis].",
"datePublished": "2024-05-06",
"url": "https://questionsmedicales.fr/article/38747608",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
},
{
"@type": "ScholarlyArticle",
"name": "Neuropsychological Manifestations of Multiple Sclerosis.",
"datePublished": "2024-06-14",
"url": "https://questionsmedicales.fr/article/39343478",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ncl.2024.05.010"
}
},
{
"@type": "ScholarlyArticle",
"name": "Biochemical biomarkers for multiple sclerosis.",
"datePublished": "2023-07-05",
"url": "https://questionsmedicales.fr/article/37419300",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cca.2023.117471"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Pigments biologiques",
"item": "https://questionsmedicales.fr/mesh/D010860"
},
{
"@type": "ListItem",
"position": 4,
"name": "Pigments biliaires",
"item": "https://questionsmedicales.fr/mesh/D001654"
},
{
"@type": "ListItem",
"position": 5,
"name": "Bilirubine",
"item": "https://questionsmedicales.fr/mesh/D001663"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Bilirubine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Bilirubine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-26",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Bilirubine",
"description": "Comment mesurer le taux de bilirubine ?\nQuels tests diagnostiques sont utilisés ?\nQu'indique un taux élevé de bilirubine ?\nQuelle est la différence entre bilirubine directe et indirecte ?\nQuels symptômes peuvent nécessiter un test de bilirubine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Multiple+Sclerosis#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Bilirubine",
"description": "Quels sont les symptômes d'une hyperbilirubinémie ?\nLa bilirubine affecte-t-elle la peau ?\nQuels signes indiquent une maladie hépatique ?\nLa bilirubine peut-elle causer des démangeaisons ?\nComment la bilirubine affecte-t-elle l'urine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Multiple+Sclerosis#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Bilirubine",
"description": "Comment prévenir l'ictère néonatal ?\nQuels examens réguliers sont recommandés ?\nComment éviter les maladies hépatiques ?\nLes vaccinations sont-elles importantes ?\nComment une alimentation saine aide-t-elle ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Multiple+Sclerosis#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Bilirubine",
"description": "Comment traiter une hyperbilirubinémie ?\nLes transfusions sanguines sont-elles nécessaires ?\nQuels médicaments peuvent réduire la bilirubine ?\nLa photothérapie est-elle efficace ?\nQuand envisager une chirurgie pour la bilirubine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Multiple+Sclerosis#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Bilirubine",
"description": "Quelles complications peuvent survenir avec une bilirubine élevée ?\nL'hyperbilirubinémie peut-elle causer des dommages cérébraux ?\nQuels sont les risques d'une obstruction biliaire ?\nComment l'hyperbilirubinémie affecte-t-elle la grossesse ?\nQuelles sont les conséquences d'une maladie hépatique avancée ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Multiple+Sclerosis#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Bilirubine",
"description": "Quels facteurs augmentent le risque d'hyperbilirubinémie ?\nL'alcoolisme est-il un facteur de risque ?\nLes infections virales influencent-elles la bilirubine ?\nLe surpoids est-il un facteur de risque ?\nLes médicaments peuvent-ils affecter la bilirubine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Multiple+Sclerosis#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment mesurer le taux de bilirubine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le taux de bilirubine est mesuré par une analyse sanguine."
}
},
{
"@type": "Question",
"name": "Quels tests diagnostiques sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la bilirubine totale et directe, ainsi que des tests hépatiques."
}
},
{
"@type": "Question",
"name": "Qu'indique un taux élevé de bilirubine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un taux élevé peut indiquer une maladie hépatique, une obstruction biliaire ou une anémie."
}
},
{
"@type": "Question",
"name": "Quelle est la différence entre bilirubine directe et indirecte ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La bilirubine directe est soluble dans l'eau, tandis que l'indirecte ne l'est pas."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent nécessiter un test de bilirubine ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme jaunisse, fatigue ou douleurs abdominales peuvent nécessiter un test."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une hyperbilirubinémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent jaunisse, urine foncée, selles claires et démangeaisons."
}
},
{
"@type": "Question",
"name": "La bilirubine affecte-t-elle la peau ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un excès de bilirubine peut provoquer un jaunissement de la peau et des yeux."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une maladie hépatique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme la fatigue, l'ictère et des douleurs abdominales peuvent indiquer une maladie hépatique."
}
},
{
"@type": "Question",
"name": "La bilirubine peut-elle causer des démangeaisons ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une accumulation de bilirubine peut provoquer des démangeaisons cutanées."
}
},
{
"@type": "Question",
"name": "Comment la bilirubine affecte-t-elle l'urine ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un taux élevé de bilirubine peut rendre l'urine foncée, semblable à celle du thé."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'ictère néonatal ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'ictère néonatal peut être prévenu par une surveillance attentive des nouveau-nés et une alimentation adéquate."
}
},
{
"@type": "Question",
"name": "Quels examens réguliers sont recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers de la fonction hépatique sont recommandés pour détecter des anomalies."
}
},
{
"@type": "Question",
"name": "Comment éviter les maladies hépatiques ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'alcool, maintenir un poids santé et se faire vacciner contre l'hépatite aide à prévenir les maladies hépatiques."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations contre l'hépatite A et B sont cruciales pour prévenir les infections hépatiques."
}
},
{
"@type": "Question",
"name": "Comment une alimentation saine aide-t-elle ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée aide à maintenir la santé du foie et à prévenir l'accumulation de bilirubine."
}
},
{
"@type": "Question",
"name": "Comment traiter une hyperbilirubinémie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dépend de la cause sous-jacente, comme des médicaments ou une intervention chirurgicale."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines sont-elles nécessaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, dans certains cas d'anémie hémolytique, des transfusions peuvent être nécessaires."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent réduire la bilirubine ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les corticostéroïdes peuvent être utilisés pour traiter certaines conditions."
}
},
{
"@type": "Question",
"name": "La photothérapie est-elle efficace ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la photothérapie est souvent utilisée pour traiter l'ictère néonatal en réduisant la bilirubine."
}
},
{
"@type": "Question",
"name": "Quand envisager une chirurgie pour la bilirubine ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie peut être envisagée en cas d'obstruction biliaire ou de maladies hépatiques graves."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une bilirubine élevée ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des lésions hépatiques, des troubles neurologiques et des infections."
}
},
{
"@type": "Question",
"name": "L'hyperbilirubinémie peut-elle causer des dommages cérébraux ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une hyperbilirubinémie sévère peut entraîner des dommages cérébraux, surtout chez les nouveau-nés."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'une obstruction biliaire ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des infections, des douleurs abdominales et des lésions hépatiques."
}
},
{
"@type": "Question",
"name": "Comment l'hyperbilirubinémie affecte-t-elle la grossesse ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des complications pour la mère et le fœtus, nécessitant une surveillance étroite."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une maladie hépatique avancée ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les conséquences incluent la cirrhose, le cancer du foie et l'insuffisance hépatique."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'hyperbilirubinémie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des maladies hépatiques, des infections et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'alcoolisme est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'alcoolisme peut endommager le foie et augmenter le risque d'hyperbilirubinémie."
}
},
{
"@type": "Question",
"name": "Les infections virales influencent-elles la bilirubine ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections comme l'hépatite peuvent augmenter les niveaux de bilirubine."
}
},
{
"@type": "Question",
"name": "Le surpoids est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le surpoids peut contribuer à des maladies hépatiques et à une hyperbilirubinémie."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils affecter la bilirubine ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent interférer avec le métabolisme de la bilirubine et augmenter ses niveaux."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 12/04/2026
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
Affiliations :
The Liver-Brain Unit "Rita-Moretti", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.
4 publications dans cette catégorie
Affiliations :
4th Department of Internal Medicine and Institute of Medical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Publications dans "Bilirubine" :
4 publications dans cette catégorie
Affiliations :
The Liver-Brain Unit "Rita-Moretti", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
The Liver-Brain Unit "Rita-Moretti", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.
Faculty of Medicine, University of Hasanuddin, Makassar 90245, Indonesia.
Molecular Biomedicine Ph.D. Program, Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Neonatology Department, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Martin, Slovakia.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Neurology Clinic, Department of Medical, Surgical and Health Sciences, University of Trieste, 34139 Trieste, Italy.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Laboratory, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Laboratory, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Photonics Center, Skolkovo Institute of Science and Technology, Moscow, Russia.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Photonics Center, Skolkovo Institute of Science and Technology, Moscow, Russia.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Italian Liver Fondation, Bldg. Q-AREA Science Park Basovizza, SS14, km. 163,5, 34149 Trieste, Italy.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Hepatic Surgery and Liver transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Publications dans "Bilirubine" :
Multiple Sclerosis (MS) is a common immune-mediated disorder of the central nervous system that affects young adults and is characterized by demyelination and neurodegeneration. Recent studies have as...
Multiple sclerosis (MS) is an autoimmune, T-cell-dependent, inflammatory, demyelinating disease of the central nervous system, with an unpredictable course. Current MS therapies focus on treating and ...
To evaluate the benefits and harms of alemtuzumab alone or associated with other treatments in people with any form of MS....
We used standard, extensive Cochrane search methods. The latest search date was 21 June 2022....
We included randomized controlled trials (RCTs) in adults with any subtype of MS comparing alemtuzumab alone or associated with other medications versus placebo; another active drug; or alemtuzumab in...
We used standard Cochrane methods. Our co-primary outcomes were 1. relapse-free survival, 2. sustained disease progression, and 3. number of participants experiencing at least one adverse event. Our s...
We included three RCTs (1713 participants) comparing intravenous alemtuzumab versus subcutaneous interferon beta-1a for relapsing-remitting MS. Participants were treatment-naive (two studies) or had e...
Compared with interferon beta-1a, alemtuzumab may improve relapse-free survival and sustained disease progression-free survival, and make little to no difference on the proportion of participants with...
Multiple sclerosis is a chronic inflammatory disease of the central nervous system, caused by an autoimmune reaction. Treatment options have largely increased over the years. In this article, we prese...
This review article summarizes the literature on the cognitive impairment seen amongst people with multiple sclerosis (MS) and how that impairment can impact not only their lives but also how their ca...
Multiple sclerosis (MS) is the most frequent demyelinating disease of the central nervous system. Although there is currently no definite cure for MS, new therapies have recently been developed based ...
MS diagnosis relies on the integration of clinical, imaging and laboratory findings as there is still no singlepathognomonicclinical feature or diagnostic laboratory biomarker. The most commonly labor...
CSF and serum biomarkers have been reviewed for their use in MS diagnosis and prognosis to stablish an accurate and prompt MS diagnosis, crucial to implement an adequate treatment and to optimize clin...
Multiple Sclerosis (MS) is a chronic neuroinflammatory disease that affects the central nervous system. Asymmetry is one of the finding in brain MRI of these patients, which is related to the debilita...
This cross-sectional study conducted on 83 patients with relapse-remitting MS (RRMS), 43 patients with secondary progressive MS (SPMS), and 89 healthy controls. The volumes of total intracranial, tota...
We showed that the normalized whole thalamic volume in healthy subjects was higher than MS patients (both RRMS and SPMS). Thalamic asymmetry index (TAI) was significantly different between RRMS patien...
In this cross-sectional study we showed a relationship between normalized whole thalamic volume and MS subtype. Also, we showed that the asymmetric indices of the thalamus can be related to the progre...
Multiple Sclerosis (MS), a chronic disease of the central nervous system (CNS), affects functional ability and quality of life (QoL). Depression, fatigue, and disability status are among the many fact...
The purpose of this study was to determine relevant predictors of QoL from a wide list of symptoms including physical disability, and a multi-dimensional computerized cognitive assessment battery (CAB...
171 people with MS (PwMS) were evaluated with a computerized assessment battery (CAB), EDSS examination, and validated Patient Reported Outcome (PRO) measures (Multiple Sclerosis Impact Scale, MSIS-29...
171 PwMS were included [Age: 46.02 years ± 9.85, 124 (72.5%) female]. Depression and fatigue scores were highly correlated with MSIS-29. EDSS, unemployment, memory, executive functioning, and motor sk...
Findings indicate the need for comprehensive and quantified evaluation of all factors associated with disease burden, which will ultimately serve to improve the QoL in PwMS through more targeted and p...
Neurological disorders, including multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), may be associated with alterations in blood cell composition and phenotype. Here, we focused our atte...
Multiple Sclerosis (MS) is an immune-mediated, chronic disease of the central nervous system that affects mainly adults. However, it is increasingly recognized that MS may start in childhood resulting...
This study was a cross-sectional study that included MS patients who visited the MS unit at Alexandria University from January 2019 to January 2021. We analyzed their epidemiological, clinical, radiol...
Annual Relapse Rate (ARR) was marginally less in POMS than AOMS (0.72 ± 0.57 vs 1.04 ± 0.78 relapse/year, P =.008). POMS patients had a bigger gap to their first relapse (40.0 ± 47.35 vs 22.71 ± 34.33...
Early disease onset does not mean a higher relapse rate when including the full spectrum of POMS and longer follow-up duration. POMS patients relapsed more on the first-line DMT and escalation should ...
Regular assessment of disease activity in relapsing-remitting multiple sclerosis (RRMS) is required to optimize clinical outcomes. Biomarkers can be a valuable tool for measuring disease activity in m...